1A11.1) - Other Forms of Botulism: Complete Clinical Coding Guide

1. Introduction

Botulism represents a serious neurological condition caused by botulinum toxin, produced by the bacterium Clostridium botulinum. While the most well-known form is foodborne intoxication, there are other forms of botulism that require specific clinical attention and appropriate coding. The ICD-11 code 1A11.1 was established to classify these less common, but equally important variants of the disease.

Other forms of botulism include wound botulism, infant botulism, adult intestinal botulism, and iatrogenic forms related to therapeutic or cosmetic use of botulinum toxin. Each of these presentations has distinct clinical characteristics, different mechanisms of acquisition, and specific therapeutic approaches.

The clinical importance of these alternative forms of botulism cannot be underestimated. Although they are less frequent than foodborne intoxication, these variants can present significant diagnostic challenges, especially when there is no clear history of foodborne exposure. Early recognition is fundamental, as untreated botulism can rapidly progress to respiratory failure and death.

Correct coding of botulism is critical for multiple aspects of medical practice. It enables appropriate epidemiological tracking, facilitates communication among healthcare professionals, aids in resource allocation for treatment and research, and ensures accurate documentation for legal and administrative purposes. The distinction between different forms of botulism also has direct implications for clinical management, epidemiological investigation, and necessary public health measures.

2. Correct ICD-11 Code

Code: 1A11.1

Description: Other forms of botulism

Parent Category: 1A11 - Botulism

This specific ICD-11 code was designated to classify all forms of botulism that do not fall under the category of food poisoning from botulinum toxin. The hierarchical structure of ICD-11 organizes botulism under the broader category of infectious diseases, recognizing its toxigenic nature.

The code 1A11.1 is used when the clinical manifestation of botulism occurs through mechanisms other than ingestion of food contaminated with preformed toxin. This includes situations where the bacterium Clostridium botulinum colonizes tissues and produces toxin in vivo, or when there is iatrogenic exposure to purified botulinum toxin.

Precision in the application of this code is fundamental to differentiate between routes of exposure and pathogenic mechanisms of botulism. This distinction is not merely academic, as it has important practical implications for source tracking, implementation of preventive measures, and treatment guidance. The parent category 1A11 encompasses all forms of botulism, but specification through code 1A11.1 allows greater granularity in clinical and epidemiological documentation.

3. When to Use This Code

The code 1A11.1 should be applied in specific clinical scenarios where botulism manifests through non-foodborne mechanisms. Below, we present detailed practical situations:

Wound Botulism: Use this code when a patient presents with neurological signs compatible with botulism and has a contaminated wound, especially deep, penetrating wounds or those with necrotic tissue. This scenario is particularly common in injectable drug users who use subcutaneous or intramuscular routes. The patient typically develops descending muscle weakness, diplopia, and dysphagia days to weeks after the injury. The absence of a history of suspicious food ingestion and the presence of an infected wound are essential criteria.

Infant Botulism: This code is appropriate for infants, usually under one year of age, who develop progressive constipation, generalized weakness, weak cry, difficulty sucking, and hypotonia. The condition results from intestinal colonization by Clostridium botulinum with in vivo toxin production. Exposure to contaminated honey or dust may be present in the history, but is not mandatory. Differential diagnosis with other causes of infantile hypotonia is crucial before applying this code.

Adult Intestinal Botulism: Use 1A11.1 when adults with anatomical or functional alterations of the gastrointestinal tract develop botulism from intestinal colonization. Patients with a history of gastrointestinal surgery, Crohn's disease, prolonged antibiotic use, or other conditions that alter intestinal microbiota may develop this rare form. The clinical presentation is similar to foodborne botulism, but without a history of ingestion of suspicious foods.

Iatrogenic Botulism: This code should be applied when systemic complications occur after therapeutic or cosmetic use of botulinum toxin. Although rare, toxin dissemination beyond the application site can occur, causing generalized botulism symptoms. Patients may present with diffuse muscle weakness, dysphagia, or respiratory difficulty after procedures with botulinum toxin, whether for treatment of dystonia, spasticity, or aesthetic purposes.

Inhalation Botulism: In exceptional situations of occupational or accidental exposure to botulinum toxin in aerosol form, code 1A11.1 is appropriate. This form is extremely rare, but can occur in laboratories or industrial settings. The clinical presentation is similar to other forms, but with potentially faster onset due to pulmonary absorption.

Botulism of Undetermined Origin: When a patient presents with unequivocal clinical manifestations of botulism, with laboratory confirmation, but it is not possible to identify the source or mechanism of exposure after complete investigation, code 1A11.1 is also applicable. This situation requires careful documentation of the investigation performed.

4. When NOT to Use This Code

It is fundamental to recognize situations where code 1A11.1 should not be applied, avoiding coding errors that may compromise clinical and epidemiological documentation.

Food Poisoning from Botulinum Toxin: Do not use 1A11.1 when there is clear evidence of ingestion of food contaminated with preformed botulinum toxin. Cases related to consumption of homemade preserves, inadequately processed canned foods, or foodborne outbreaks should be coded as 1A11.0. The fundamental distinction is the ingestion of preformed toxin versus in vivo toxin production.

Neurological Conditions that Mimic Botulism: Various conditions may present symptoms similar to botulism and should not receive this code. Guillain-Barré syndrome, myasthenia gravis, Eaton-Lambert syndrome, organophosphate poisoning, brainstem stroke, and tick paralysis may cause muscle weakness and similar neurological symptoms. Diagnostic confirmation through specific laboratory tests is essential before applying code 1A11.1.

Local Reactions to Botulinum Toxin: Localized adverse effects following therapeutic or cosmetic application of botulinum toxin, without signs of systemic dissemination, should not be coded as botulism. Localized ptosis, muscle weakness restricted to the application site, or other expected effects of the procedure require codes for procedure complications, not infectious disease.

Asymptomatic Colonization: Detection of Clostridium botulinum in cultures without clinical manifestations of botulism does not justify the use of this code. Asymptomatic intestinal colonization, especially in infants, may occur without significant toxin production or clinical symptoms.

5. Step-by-Step Coding Process

Step 1: Assess Diagnostic Criteria

The first essential step is to confirm that the patient truly presents with botulism. The evaluation should include identification of characteristic neurological symptoms: symmetric descending muscle weakness, cranial nerve paralysis (diplopia, ptosis, dysarthria, dysphagia), absence of fever, preserved sensorium, and normal or diminished tendon reflexes.

Laboratory confirmation is fundamental, although treatment should not be delayed awaiting results. Request detection of botulinum toxin in serum, feces, or wound material, as appropriate. Culture of Clostridium botulinum may be performed, but absence of growth does not exclude the diagnosis. Electromyography can demonstrate the characteristic pattern of incremental facilitation with high-frequency repetitive stimulation.

Carefully evaluate the clinical history to identify possible non-foodborne sources of exposure. Question regarding recent wounds, injectable drug use, botulinum toxin procedures, prior gastrointestinal surgeries, and in infants, exposure to honey or environments with contaminated dust.

Step 2: Verify Specifiers

Determine the specific form of botulism present. Classify as wound botulism if there is contaminated injury; infant botulism if the patient is an infant with intestinal colonization; adult intestinal botulism if there are predisposing gastrointestinal conditions; or iatrogenic botulism if related to medical procedures.

Assess the severity of clinical presentation. Document whether there is respiratory compromise, need for mechanical ventilation, degree of muscle weakness, and involvement of cranial nerves. This information, although it does not change the primary code, is crucial for complete documentation.

Record the duration of symptoms from onset to presentation, as this aids in diagnostic confirmation and has prognostic implications. Botulism typically evolves over days, with characteristic symptom progression.

Step 3: Differentiate from Other Codes

Differentiation from code 1A11.0 (Foodborne intoxication by botulinum toxin): The fundamental distinction lies in the mechanism of acquisition. Code 1A11.0 is reserved for cases where there is ingestion of food contaminated with preformed botulinum toxin. Multiple cases related to the same food source, history of consumption of high-risk foods (homemade preserves, damaged canned goods), and absence of other sources of exposure indicate 1A11.0.

In contrast, 1A11.1 is used when toxin is produced in vivo following colonization by Clostridium botulinum (infant botulism, adult intestinal botulism, wound botulism) or when there is iatrogenic exposure to purified toxin. Absence of suspicious food history and the presence of risk factors for non-foodborne forms are indicative of 1A11.1.

In situations where epidemiological investigation does not clearly identify the source, but clinical and epidemiological characteristics more strongly suggest a non-foodborne form, code 1A11.1 is more appropriate.

Step 4: Required Documentation

For appropriate coding with 1A11.1, medical documentation must include:

Checklist of Mandatory Information:

Detailed description of neurological symptoms present
Chronology of symptom evolution
Complete neurological examination, including cranial nerves and muscle strength
Relevant exposure history (wounds, procedures, intestinal risk factors)
Explicit exclusion of suspicious food ingestion
Results of laboratory tests (toxin, cultures, electromyography)
Differential diagnoses considered and excluded
Justification for classification as non-foodborne form of botulism
Treatment instituted and clinical response

Clearly document the specific form of botulism identified (wound, infant, intestinal, iatrogenic) in the medical record, as although all use code 1A11.1, this specification is important for clinical management and epidemiological investigation.

6. Complete Practical Example

Clinical Case:

A 28-year-old male patient is admitted to the emergency department with complaints of double vision and difficulty swallowing with three days of evolution. He reports that approximately ten days ago he sustained a deep penetrating wound to the left forearm with a contaminated object while working in a rural area. He superficially cleaned the wound but did not seek medical attention. Two days ago, he noticed that the wound presented purulent discharge and necrotic appearance.

On physical examination, the patient is conscious, oriented, and afebrile. He presents with bilateral ptosis, diplopia, moderate dysarthria, and dysphagia. Muscle strength is globally diminished, more evident in proximal musculature of the upper limbs. Tendon reflexes are present but hypoactive. On the left forearm, a wound of approximately 3 cm is observed, with necrotic borders, purulent discharge, and local signs of inflammation.

General laboratory tests show mild leukocytosis. Electromyography demonstrates a pattern of incremental facilitation with high-frequency repetitive stimulation, compatible with presynaptic neuromuscular blockade. Serum samples and wound material were collected for detection of botulinum toxin and culture of Clostridium botulinum.

The patient denies consumption of canned foods, homemade preserves, or other risk foods in recent days. He does not use injectable drugs. He has not undergone procedures with botulinum toxin. He has no history of gastrointestinal surgeries or intestinal diseases.

Step-by-Step Coding:

Criteria Analysis:

First, we confirm the presence of neurological symptoms characteristic of botulism: paralysis of cranial nerves (ptosis, diplopia, dysarthria, dysphagia), descending muscle weakness, preserved but diminished reflexes, normal sensorium, and absence of fever. The electromyography pattern is highly suggestive of botulism.

Second, we identify the presence of a deep penetrating wound with signs of infection and necrosis, occurring approximately one week before the onset of neurological symptoms. The temporal interval is compatible with wound botulism, where there is an incubation period between wound contamination and production of sufficient toxin to cause systemic symptoms.

Third, we explicitly exclude other forms of botulism. There is no history of suspicious food ingestion, ruling out foodborne botulism (1A11.0). The patient is not an infant, excluding infant botulism. There are no risk factors for adult intestinal botulism. There was no iatrogenic exposure to botulinum toxin.

Selected Code: 1A11.1 - Other forms of botulism

Complete Justification:

This case clearly represents wound botulism, one of the forms included in code 1A11.1. The presence of a contaminated wound with signs of anaerobic infection, associated with the subsequent development of typical neurological symptoms of botulism, establishes the diagnosis. The absence of suspicious food history and other exposure mechanisms confirms that this is not foodborne intoxication (1A11.0).

Code 1A11.1 is the most appropriate because it adequately captures the pathophysiological mechanism involved: colonization of damaged tissue by Clostridium botulinum with local toxin production and subsequent systemic dissemination. This distinction has important implications for management, including the need for surgical debridement of the wound in addition to administration of botulinum antitoxin.

Complementary Codes:

In addition to the primary code 1A11.1, the following should be included:

Code for infected wound of the forearm (specifying location and nature)
Code for respiratory insufficiency if ventilatory support is required
Codes for procedures performed (surgical debridement, antitoxin administration)

Documentation should include detailed description of the wound, temporal evolution of symptoms, physical examination findings, results of complementary tests, and justification for classification as wound botulism.

7. Related Codes and Differentiation

Within the Same Category:

1A11.0: Food poisoning by botulinum toxin

The differentiation between 1A11.0 and 1A11.1 is fundamental and is based primarily on the mechanism of toxin acquisition. Code 1A11.0 is reserved exclusively for cases where there is ingestion of food contaminated with preformed botulinum toxin. Characteristics that indicate 1A11.0 include: history of consumption of high-risk foods (homemade preserves, damaged canned goods, inadequately fermented foods), multiple cases related to the same food source, symptom onset typically 12 to 36 hours after ingestion, and epidemiological investigation that identifies contaminated food.

In contrast, 1A11.1 is used when botulism results from in vivo toxin production following bacterial colonization (wounds, intestine) or iatrogenic exposure. Distinctive characteristics include: absence of suspicious food history, presence of infected wounds or intestinal risk factors, isolated cases without relation to common food exposure, and variable incubation period depending on the specific form.

The main difference is not in the clinical presentation, which may be identical, but rather in the epidemiological context and pathophysiological mechanism. This distinction is crucial for public health investigation, as foodborne botulism requires tracking of contaminated foods and possible product recall, while other forms require different approaches.

Differential Diagnoses:

Guillain-Barré Syndrome: Differentiated by the presence of paresthesias, ascending progression of weakness, albumin-cytological dissociation in cerebrospinal fluid, and demyelinating pattern on electroneuromyography. Botulism typically does not cause sensory changes and presents a presynaptic neuromuscular pattern.

Myasthenia Gravis: Can cause fluctuating weakness and ptosis, but generally responds to anticholinesterase testing, presents specific antibodies, and has a more chronic course. Botulism does not respond to anticholinesterases and has a more acute onset.

Organophosphate Poisoning: Presents with miosis, fasciculations, hypersecretion, and cholinergic symptoms that do not occur in botulism, where mydriasis and dry mouth are present.

8. Differences with ICD-10

In ICD-10, botulism was coded under A05.1 for foodborne botulism. Other forms of botulism did not have a separate specific code, often being coded also under A05.1 or occasionally under less specific codes for clostridial infections.

ICD-11 introduces greater specificity with the creation of distinct codes: 1A11.0 for foodborne botulinum toxin poisoning and 1A11.1 for other forms of botulism. This change represents a significant advancement in the ability to epidemiologically differentiate the different forms of the disease.

The main changes include formal recognition of non-foodborne forms as a distinct category, better alignment with current pathophysiological understanding of the disease, and facilitation of epidemiological studies specific to each form of botulism.

The practical impact of these changes includes better tracking of wound botulism cases (especially those related to injectable drug use), more precise monitoring of infantile botulism, and identification of iatrogenic complications related to therapeutic use of botulinum toxin. This specificity allows for more targeted allocation of public health resources and development of preventive strategies specific to each form of the disease.

9. Frequently Asked Questions

How is the diagnosis of other forms of botulism made?

The diagnosis is based on the combination of characteristic clinical presentation, relevant exposure history, and laboratory confirmation. Clinically, the pattern of symmetric descending muscle weakness, cranial nerve paralysis, absence of fever, and preserved sensorium is sought. The history should investigate recent wounds, especially in injectable drug users, or in infants, exposure to honey and dust. Laboratory confirmation involves detection of botulinum toxin in serum, feces, or wound material, in addition to culture of Clostridium botulinum. Electroneuromyography can demonstrate the characteristic pattern of incremental facilitation. It is important to emphasize that treatment should not be delayed awaiting laboratory confirmation, as tests may take days and early intervention is crucial.

Is treatment available in public health systems?

Botulism treatment is generally available in public health systems, although the availability of specific botulinum antitoxin may vary regionally. Management includes intensive supportive care, administration of botulinum antitoxin when indicated, and specific treatment according to the form. In wound botulism, surgical debridement of necrotic tissue is essential, in addition to appropriate antibiotic therapy. In infantile botulism, human botulinum immunoglobulin can be used when available. Many health systems maintain strategic stocks of antitoxin or have protocols for rapid access in emergencies. Treatment requires hospital admission, often in an intensive care unit, with ventilatory support when necessary.

How long does treatment and recovery take?

The duration of treatment and recovery from botulism is variable, depending on severity and specific form. The acute phase generally requires hospitalization for weeks to months. Patients requiring mechanical ventilation may remain ventilator-dependent for weeks. Neurological recovery occurs gradually as new nerve terminals are formed, a process that may take months. Muscle weakness improves slowly, with complete recovery potentially taking three to six months or more. Physical therapy and rehabilitation are important components of recovery. In infantile botulism, recovery tends to be faster and more complete than in adults. Permanent sequelae are rare when appropriate treatment is instituted early, but fatigue and weakness may persist for a prolonged period.

Can this code be used in medical certificates?

Yes, code 1A11.1 can and should be used in official medical documentation, including certificates, when appropriate. However, considerations regarding confidentiality and stigma should be weighed, especially in cases of wound botulism related to injectable drug use. In certificates for work purposes, it may be sufficient to document "severe neurological disease" or "bacterial toxin infection" without specifying botulism, depending on circumstances and patient needs. For medical, insurance, and hospital documentation purposes, precise coding is essential. The decision regarding the level of specificity in different documents should balance the need for accurate medical information with protection of patient privacy and prevention of discrimination.

What is the difference between infantile botulism and adult intestinal botulism?

Both forms involve intestinal colonization by Clostridium botulinum with in vivo toxin production, but occur in different populations with distinct risk factors. Infantile botulism affects infants, typically under one year of age, whose intestinal microbiota is not yet fully established, allowing bacterial colonization. Exposure to honey is a known risk factor, but many cases occur without an identified source. Presentation includes constipation, weakness, weak cry, and progressive hypotonia. Adult intestinal botulism is extremely rare and occurs in individuals with anatomical or functional alterations of the gastrointestinal tract, such as previous surgery, inflammatory bowel disease, or prolonged antibiotic use that alters the microbiota. Both are coded as 1A11.1, but the distinction is important for management and prognosis.

Is iatrogenic botulism common after aesthetic procedures?

Iatrogenic botulism following cosmetic or therapeutic use of botulinum toxin is extremely rare when the product is used appropriately by qualified professionals. The purified botulinum toxin used in medical procedures is highly controlled and standardized. Local adverse effects are relatively common and expected, but systemic dissemination causing true botulism is exceptional. Reported cases generally involve excessive doses, inadequate technique, unregulated products, or patients with predisposing conditions. Symptoms of systemic botulism (generalized weakness, respiratory difficulty, dysphagia) following procedures with botulinum toxin require immediate medical evaluation. The majority of patients undergoing procedures with botulinum toxin will not develop systemic complications.

How to differentiate wound botulism from common wound infection?

Differentiation is based on the presence of systemic neurological symptoms in wound botulism, absent in common wound infections. Typical bacterial wound infections cause local signs (pain, erythema, edema, purulent discharge) and may cause fever and systemic symptoms of infection, but do not cause cranial nerve paralysis or descending muscle weakness. In wound botulism, neurological symptoms generally appear days to weeks after the wound, even when local signs of infection may be minimal. The presence of diplopia, ptosis, dysphagia, and progressive muscle weakness in a patient with a wound, especially a deep wound or one with necrotic tissue, should raise suspicion for wound botulism. Confirmation requires detection of toxin or culture of Clostridium botulinum from wound material.

Is isolation of the patient with botulism necessary?

No, botulism is not a disease transmissible between people. The patient with botulism does not pose a transmission risk to other patients, visitors, or healthcare professionals. Standard infection control precautions are sufficient. There is no need for respiratory isolation, contact isolation, or any type of special isolation. This characteristic distinguishes botulism from many other infectious diseases. However, in cases of wound botulism, appropriate management of the infected wound requires standard precautions to prevent contamination. The absence of need for isolation facilitates the intensive care often necessary and allows important family visits for psychological support of the patient during prolonged hospitalization.

Note: This article provides general guidance on clinical coding. Diagnostic and therapeutic decisions should always be individualized and based on complete clinical evaluation by a qualified professional. Coding should accurately reflect clinical documentation and follow applicable institutional and regulatory guidelines.

External References

This article was developed based on reliable scientific sources:

🌍 WHO ICD-11 - Other forms of botulism
🔬 PubMed Research on Other forms of botulism
🌍 WHO Health Topics
📋 CDC - Centers for Disease Control
📊 Clinical Evidence: Other forms of botulism
📋 Ministry of Health - Brazil
📊 Cochrane Systematic Reviews

References verified on 2026-02-04

Other forms of botulism

Compartir